ArticleBlood advances2023

The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study.

Nobuko Hijiya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.